| COVID-19 | Coronavirus Disease 2019 |
| mRNA | Messenger ribonucleic acid |
| AIRDs | Autoimmune inflammatory rheumatic diseases |
| EULAR | European Alliance of Associations for Rheumatology |
| SARS-CoV-2 | Severe Acute Respiratory Syndrome Coronavirus 2 |
| PV | Pharmacovigilance |
| VAERS | Vaccine Adverse Event Reporting System |
| PRISMA | Preferred Reporting Items for Systematic Reviews and Meta-Analyses |
| ICTPR | International Clinical Trials Registry Platform |
| STROBE | Strengthening the Reporting of Observational Studies in Epidemiology |
| READUS-PV | Reporting of Evidence-based Disproportionality Analyses for Pharmacovigilance |
| ROBINS-I | Risk Of Bias In Non-randomized Studies-of Interventions |
| RoB2 | Risk of Bias 2 |
| RCT | Randomised controlled trials |
| ROR | Reporting odds ratio |
| PRR | Proportional reporting ratio |
| IC | Information component |
| SLE | Systemic lupus erythematosus |